Senti Biosciences is trading at $0.17, down 10.24%, with no fresh company-specific catalyst identified for the October 23 decline. - Merger and reverse-split approvals were reported earlier. - Broader risk-off sentiment followed sharp technology-market losses and rising oil prices, but available market data does not establish a direct cause for the stock’s move. - The decline extends recent weakness: shares closed at $0.19 on October 22, down 12.41%. Volume information was unavailable.